TY - JOUR
T1 - Comparison of 3-drug versus 4-drug and PI versus non-PI combinations as initial HAART
T2 - Experience from 1998 to 2007
AU - Jhaveri, Malhar A.
AU - Browning, Steven R.
AU - Bush, Heather
AU - Thornton, Alice
AU - Greenberg, Richard N.
PY - 2009/9
Y1 - 2009/9
N2 - Although established in controlled studies that there is no advantage to 4-drug highly active antiretroviral therapy (HAART) or regimens with or without protease inhibitors (PIs), we questioned this finding in a clinical setting (ie, no inclusion criteria). Ours is a single clinic retrospective study including all participants >18 years of age during their first year of HAART. A total of 190 participants were reviewed, with 168 (88%) attaining a viral load <400 copies/mL at the end of a year of HAART; 144 of 164 (88%) succeeded with 3 drugs and 24 of 26 (92%) with 4 drugs (P =.51). In all, 59 of 71 (83%) succeeded using a PI versus 109 of 119 (92%) without a PI (P =.08). Male gender and exposure time to HAART were significant variables for a successful outcome. Failures were due to side effects (50%), nonadherence (45%), and drug allergy (5%). Our results support current guidelines recommending 3-drug HAART.
AB - Although established in controlled studies that there is no advantage to 4-drug highly active antiretroviral therapy (HAART) or regimens with or without protease inhibitors (PIs), we questioned this finding in a clinical setting (ie, no inclusion criteria). Ours is a single clinic retrospective study including all participants >18 years of age during their first year of HAART. A total of 190 participants were reviewed, with 168 (88%) attaining a viral load <400 copies/mL at the end of a year of HAART; 144 of 164 (88%) succeeded with 3 drugs and 24 of 26 (92%) with 4 drugs (P =.51). In all, 59 of 71 (83%) succeeded using a PI versus 109 of 119 (92%) without a PI (P =.08). Male gender and exposure time to HAART were significant variables for a successful outcome. Failures were due to side effects (50%), nonadherence (45%), and drug allergy (5%). Our results support current guidelines recommending 3-drug HAART.
KW - HIV
KW - nucleoside reverse transcriptase inhibitors
KW - protease inhibitors
KW - treatment naive
UR - http://www.scopus.com/inward/record.url?scp=75349091279&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=75349091279&partnerID=8YFLogxK
U2 - 10.1177/1545109709345666
DO - 10.1177/1545109709345666
M3 - Article
C2 - 19759256
AN - SCOPUS:75349091279
SN - 1545-1097
VL - 8
SP - 299
EP - 307
JO - Journal of the International Association of Physicians in AIDS Care
JF - Journal of the International Association of Physicians in AIDS Care
IS - 5
ER -